Agonist
Back to library
GLP-1Subcutaneous

Survodutide

Also known as: BI 456906 · Survo

Dual glucagon and GLP-1 receptor agonist in Phase 3 trials for obesity and MASH. The glucagon arm increases resting energy expenditure and accelerates hepatic lipid clearance; the GLP-1 arm covers satiety and glycemia.

At a glance

Half-life
6 days
Common route
Subcutaneous
Typical dose range
600–6,000mcg
Stability (reconstituted)
30days refrigerated

Best timing

Once weekly. Trial protocols escalate every 2 weeks — community reports significant nausea with faster titration.

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2
  • History of pancreatitis
  • Active hepatic decompensation
  • Pregnancy

Watch symptoms

  • Nausea, vomiting, diarrhea (often more pronounced than pure GLP-1s)
  • Heart rate elevation from glucagon component
  • Transient elevations in liver enzymes
  • Hypoglycemia if stacked with insulin
  • Fatigue during titration

Citations

The primary literature.

  1. 01Survodutide for the treatment of obesity in adults without type 2 diabetes (Phase 2)PubMed
  2. 02Survodutide for MASH: a Phase 2 trialPubMed
Back to library